|Bid||76.69 x 1000|
|Ask||77.90 x 800|
|Day's Range||76.50 - 78.29|
|52 Week Range||71.35 - 131.95|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||17.19|
|Earnings Date||Apr 27, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||108.56|
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29, at 4:30 p.m. ET to discuss first quarter 2021 financial results and provide a general business update.
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The Palm Beach Hedge Fund Association, a Florida trade association for financial professionals and ultra high net worth investors, hosted a fireside chat Tuesday, […]
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.